Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Sun Yat-sen University
Infinity Pharmaceuticals, Inc.
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Jules Bordet Institute
Trans Tasman Radiation Oncology Group
University College, London
Jiangsu HengRui Medicine Co., Ltd.
Centre Hospitalier Universitaire de Besancon
Fudan University
Universitätsmedizin Mannheim
Tianjin Medical University Second Hospital
Tianjin Medical University Second Hospital
Asan Medical Center
Kidney Cancer Research Bureau
Herlev and Gentofte Hospital
Tianjin Medical University Cancer Institute and Hospital
MultiVir, Inc.
West China Hospital
Zhejiang Cancer Hospital
The Netherlands Cancer Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Peking University Cancer Hospital & Institute
Tianjin Medical University Cancer Institute and Hospital
Peking University Cancer Hospital & Institute
Auckland District Health Board
Southern China Urology Cancer Consortium
University of Aarhus
Associació per a la Recerca Oncologica, Spain
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Radboud University Medical Center
Association of Urologic Oncology (AUO)
Korean Urological Oncology Society
Asan Medical Center